These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33532735)

  • 1. Evaluation of the binding affinity of E3 ubiquitin ligase ligands by cellular target engagement and in-cell ELISA assay.
    Yang K; Zhou Y; Roberts BL; Nie X; Tang W
    STAR Protoc; 2021 Mar; 2(1):100288. PubMed ID: 33532735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
    Guenette RG; Potts PR
    Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.
    Mi D; Li Y; Gu H; Li Y; Chen Y
    Eur J Med Chem; 2023 Aug; 256():115444. PubMed ID: 37178483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
    Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
    Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A High-Throughput Method to Prioritize PROTAC Intracellular Target Engagement and Cell Permeability Using NanoBRET.
    Vasta JD; Corona CR; Robers MB
    Methods Mol Biol; 2021; 2365():265-282. PubMed ID: 34432249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Ligands for Ubiquitin Ligases Using Affinity Beads.
    Dobrodziej J; Dong H; Zimmermann K; Hickey CM
    Methods Mol Biol; 2021; 2365():59-75. PubMed ID: 34432239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins.
    Ng YLD; Bricelj A; Jansen JA; Murgai A; Peter K; Donovan KA; Gütschow M; Krönke J; Steinebach C; Sosič I
    J Med Chem; 2023 Apr; 66(7):4703-4733. PubMed ID: 36996313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing targeted protein degrader discovery by measuring cereblon engagement in cells.
    Zerfas BL; Huerta F; Liu H; Du G; Gray NS; Jones LH; Nowak RP
    Methods Enzymol; 2023; 681():169-188. PubMed ID: 36764756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
    Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
    Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rise of covalent proteolysis targeting chimeras.
    Gabizon R; London N
    Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible Assembly of Proteolysis Targeting Chimeras.
    Gui W; Giardina SF; Balzarini M; Barany F; Kodadek T
    ACS Chem Biol; 2023 Jul; 18(7):1582-1593. PubMed ID: 37422908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications and Limitations of Oxime-Linked "Split PROTACs".
    Gui W; Kodadek T
    Chembiochem; 2022 Sep; 23(18):e202200275. PubMed ID: 35802347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.